AR028357A1 - 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol - Google Patents

4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol

Info

Publication number
AR028357A1
AR028357A1 ARP010101869A ARP010101869A AR028357A1 AR 028357 A1 AR028357 A1 AR 028357A1 AR P010101869 A ARP010101869 A AR P010101869A AR P010101869 A ARP010101869 A AR P010101869A AR 028357 A1 AR028357 A1 AR 028357A1
Authority
AR
Argentina
Prior art keywords
fenoxi
bencil
hidroxi
etil
piperidin
Prior art date
Application number
ARP010101869A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR028357A1 publication Critical patent/AR028357A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50Aroyl radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP010101869A 2000-04-25 2001-04-23 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol AR028357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25

Publications (1)

Publication Number Publication Date
AR028357A1 true AR028357A1 (es) 2003-05-07

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101869A AR028357A1 (es) 2000-04-25 2001-04-23 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol

Country Status (18)

Country Link
US (1) US6432985B2 (enExample)
EP (1) EP1278730B1 (enExample)
JP (1) JP3831255B2 (enExample)
KR (1) KR100527527B1 (enExample)
CN (1) CN1178914C (enExample)
AR (1) AR028357A1 (enExample)
AT (1) ATE313527T1 (enExample)
AU (1) AU785153B2 (enExample)
BR (1) BR0110233A (enExample)
CA (1) CA2407345C (enExample)
DE (1) DE60116080T2 (enExample)
DK (1) DK1278730T3 (enExample)
ES (1) ES2254422T3 (enExample)
MX (1) MXPA02010573A (enExample)
PE (1) PE20011229A1 (enExample)
UY (1) UY26681A1 (enExample)
WO (1) WO2001081309A2 (enExample)
ZA (1) ZA200208134B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1585430B1 (en) 2002-11-14 2017-01-11 Brainsgate Ltd. Surgical tools and techniques for stimulation
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
AU2009228660B2 (en) * 2008-03-27 2012-11-29 Evotec International Gmbh Methods for treating disorders using NMDA NR2B-subtype selective antagonist
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
ES2463766T3 (es) * 2008-08-12 2014-05-29 Zinfandel Pharmaceuticals, Inc. Método de identificación de factores de riesgo de la enfermedad de Alzheimer
WO2012096873A1 (en) 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11319314B2 (en) 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
DE60116080D1 (de) 2006-01-26
ATE313527T1 (de) 2006-01-15
BR0110233A (pt) 2003-01-21
US20010047014A1 (en) 2001-11-29
AU785153B2 (en) 2006-10-05
PE20011229A1 (es) 2001-12-08
KR100527527B1 (ko) 2005-11-09
CA2407345A1 (en) 2001-11-01
JP3831255B2 (ja) 2006-10-11
ZA200208134B (en) 2004-01-22
AU6021301A (en) 2001-11-07
CN1443166A (zh) 2003-09-17
DK1278730T3 (da) 2006-05-01
KR20040007216A (ko) 2004-01-24
EP1278730A2 (en) 2003-01-29
MXPA02010573A (es) 2003-03-10
WO2001081309A2 (en) 2001-11-01
US6432985B2 (en) 2002-08-13
ES2254422T3 (es) 2006-06-16
CN1178914C (zh) 2004-12-08
WO2001081309A3 (en) 2002-01-17
EP1278730B1 (en) 2005-12-21
CA2407345C (en) 2009-04-07
JP2004509837A (ja) 2004-04-02
DE60116080T2 (de) 2006-08-24
UY26681A1 (es) 2001-10-25

Similar Documents

Publication Publication Date Title
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
MX242679B (es) Antranilamidas insecticidas.
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
ATE307121T1 (de) Substituierte arylpyrazine
FI20000004A0 (fi) Flavonoidilääke...
AR028393A1 (es) Iminoazidas substituidas
AR028357A1 (es) 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol
DE50112662D1 (de) Substituierte benzoylcyclohexenone
AR028302A1 (es) Feniluracilos substituidos
CH695519A5 (de) Sperrstromthyristor.
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
ES1046567Y (es) Tromel deshidratador perfeccionado.
ES1046656Y (es) Microplanta de transferencia de residuos solidos urbanos.
ES1047305Y (es) Embudo anti-rebosamiento.
IT1316979B1 (it) Grigliatrice.
ES1049032Y (es) Bitubo.
ES1047836Y (es) Hidrobicicleta.
ES1047010Y (es) Portalamparas.
ES1045851Y (es) Cubitera.
IT249307Y1 (it) Ciabatta.
ES1047650Y (es) Sacacorchos mejorado.
ES1045935Y (es) Pupitre-silla mejorado.
ES1046417Y (es) Maquina recrativa.
AR027834A1 (es) Mediastinoscopio transhiatal.

Legal Events

Date Code Title Description
FG Grant, registration